Skip to main content
. 2011 Feb 18;6(2):e16596. doi: 10.1371/journal.pone.0016596

Figure 5. Repression of chemokine CCL3/4 induction caused by Syk inhibition and silencing.

Figure 5

(A) CCL3 secretion in SUDHL4 induced by anti-IgG antibodies and anti-CD20 antibodies and its inhibition by Syk inhibitors I and IV (Calbiochem) at 1 µM and 0,32 µM respectively. Bars represent mean of three replicates, including standard deviation (<IgG>  =  anti-IgG antibody, Inh. I  =  Syk inhibitor I, Inh. IV =  Syk inhibitor IV, LT20  =  murine anti-CD20 antibody, Rx-Fab'2  =  F(ab')2 fragment of rituximab). Inhibition of CCL3 (B) and CCL4 (C) secretion in SUDHL4 induced by anti-IgG antibodies or rituximab after siRNA-mediated Syk silencing. Results represent at least three independent experiments. Students t-test for “Negative controls” vs. “SYK-knockdown”: for CCL3 secretion after anti-IgG treatment p = 6.8*10−7, Rx treatment p = 7.4*10−3. For CCL4 secretion after anti-IgG treatment p = 2.1*10−6, Rx treatment p = 2.5*10−4. (anti-IgG  =  anti-IgG antibody, Rx  =  rituximab, Neg. controls  =  RISCfree and Luciferase-siRNA transfections, respectively; SYK knock down  =  Syk-siRNA transfections).